Market Price

11.80 

0.42 3.7%

as of Feb 15 '19

52 Week Range:

9.14 19.97


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 0.37
0.35
0.35
0.29
0.52
0.62
0.31
-0.01
0.12
0.28
0.75
growth rate -5.4% 0.0% -17.1% 79.3% 19.2% -50.0% -100.0% 100.0% 133.3% 167.9%
Earnings BIT -11.57
-20.06
-20.17
-25.97
-32.35
-38.05
-46.01
-27.62
-3.44
10.18
52.86
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 419.3%
Avg.PE -6.70
-4.90
-3.40
-8.60
-9.60
0.00
-2.93
-2.93
-2.93
249.74
15.20
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -93.9%
ROA -83.72
-106.94
-91.07
-104.67
-99.65
-54.75
-56.72
-64.24
-14.80
13.49
89.27
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 561.8%
ROE -109.73
-126.80
-103.42
-119.84
-115.44
-78.79
-111.15
-356.04
-84.82
27.19
111.15
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 308.8%
ROIC -115.86
-126.62
-103.36
-119.84
-115.44
-45.36
-55.50
-63.80
-9.00
22.74
111.17
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 388.9%
Cur. Ratio 5.90
6.84
10.10
6.48
7.91
11.37
4.58
2.23
2.35
2.40
4.20
growth rate 15.9% 47.7% -35.8% 22.1% 43.7% -59.7% -51.3% 5.4% 2.1% 75.0%
Quick Ratio 5.80
6.40
9.87
6.37
7.89
11.20
4.42
2.03
2.23
2.24
3.95
growth rate 10.3% 54.2% -35.5% 23.9% 42.0% -60.5% -54.1% 9.9% 0.5% 76.3%
Leverage 1.20
1.17
1.11
1.18
1.14
1.61
3.00
2.81
1.66
1.15
growth rate -2.5% -5.1% 6.3% -3.4% 41.2% 86.3% -3.2% -40.9% -30.7%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 0.00
0.00
0.00
0.00
0.56
1.43
3.33
6.22
9.86
15.30
growth rate 156.4% 133.5% 86.6% 58.5% 55.2%
Acct.Payable 5.03
5.69
6.97
1.89
1.33
2.29
8.58
growth rate 13.3% 22.4% -72.9% -29.8% 72.8% 274.6%
Cur.Assets 19.60
24.40
25.00
39.78
95.06
58.31
30.23
48.98
65.69
124.19
growth rate 24.5% 2.5% 59.1% 139.0% -38.7% -48.2% 62.0% 34.1% 89.1%
Total Assets 19.80
24.50
25.10
39.83
99.17
63.08
34.63
51.90
68.75
220.54
growth rate 23.7% 2.5% 58.7% 149.0% -36.4% -45.1% 49.9% 32.5% 220.8%
Cash 14.70
23.90
24.60
39.64
93.03
54.88
24.25
40.44
51.54
31.06
growth rate 62.6% 2.9% 61.1% 134.7% -41.0% -55.8% 66.8% 27.5% -39.7%
Inventory 0.00
0.00
0.00
0.00
0.85
1.10
1.21
1.68
2.33
4.58
growth rate 28.5% 10.1% 39.4% 38.5% 96.5%
Cur.Liabilities 2.90
2.40
3.90
5.03
8.36
12.74
13.56
20.88
27.37
29.57
growth rate -17.2% 62.5% 28.9% 66.3% 52.4% 6.4% 54.0% 31.1% 8.0%
Liabilities 2.90
2.40
3.90
5.03
37.39
42.06
38.02
33.40
27.37
29.57
growth rate -17.2% 62.5% 28.9% 643.9% 12.5% -9.6% -12.1% -18.1% 8.0%
LT Debt 0.02
0.00
0.00
0.00
0.00
29.03
29.32
24.46
12.53
growth rate -100.0% 1.0% -16.6% -48.8%
Equity 14.73
16.90
22.10
21.20
34.81
61.78
21.02
-3.39
18.50
41.38
190.97
growth rate 14.7% 30.8% -4.1% 64.2% 77.5% -66.0% -100.0% 100.0% 123.7% 361.5%
Common Shares 34.00
47.00
52.00
68.00
83.00
93.00
100.00
101.00
107.00
116.00
125.00
growth rate 38.2% 10.6% 30.8% 22.1% 12.1% 7.5% 1.0% 5.9% 8.4% 7.8%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Capital Expenditures 0.00
0.00
0.00
0.00
0.03
0.15
0.13
0.17
0.02
0.19
0.42
growth rate 504.0% -15.9% 37.0% -90.2% 1,041.2% 116.0%
Cash Dividends 0.00 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA -10.96
-18.36
-17.97
-22.29
-27.40
-36.02
-27.38
3.13
18.39
60.94
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 487.6% 231.3%
FCF per Share -0.32
-0.39
-0.34
-0.31
-0.32
-0.39
-0.38
-0.34
-0.02
0.16
0.33
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 106.3%
Sale Purchase of Stock 42.48
59.71
0.06
1.78
22.28
7.68
7.18
growth rate 40.6% -99.9% 3,130.9% 1,153.9% -65.5% -6.5%
FCF -11.00
-18.00
-18.00
-22.00
-27.00
-36.00
-37.00
-28.00
3.00
18.00
61.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 500.0% 238.9%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 0.48
0.20
0.03
0.00
0.00
3.31
10.36
26.55
50.29
81.32
159.20
growth rate -58.5% -85.0% -100.0% 213.2% 156.4% 89.4% 61.7% 95.8%
Op.Income -19.70
-20.30
-27.40
-32.35
-38.05
-46.01
-27.62
-3.44
10.18
52.86
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 419.3%
IBT 0.00
0.00
-26.00
-32.35
-38.05
-46.01
-31.38
-6.41
8.14
52.81
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 548.7%
Net Income -20.10
-20.20
-26.00
-32.35
-38.05
-46.01
-31.38
-6.41
8.14
129.12
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 1,486.3%
EPS -0.34
-0.43
-0.38
-0.38
-0.39
-0.41
-0.46
-0.31
-0.06
0.07
1.04
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 1,385.7%
Gross Profit 0.48
0.20
0.03
0.00
0.00
3.22
10.21
25.67
48.93
79.26
155.65
growth rate -58.3% -85.0% -100.0% 217.6% 151.3% 90.6% 62.0% 96.4%
R&D 14.20
14.40
18.90
21.00
14.07
20.47
18.37
15.42
23.84
40.38
growth rate 1.4% 31.3% 11.1% -33.0% 45.5% -10.3% -16.1% 54.6% 69.3%

Quarterly Statements

Item Name Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Earnings BIT 13.62
21.70
21.00
20.63
22.97
growth rate 59.3% -3.2% -1.7% 11.3%
Balance Sheet Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Acct.Receivable 11.87
15.30
17.26
28.70
19.36
growth rate 28.9% 12.8% 66.3% -32.6%
Acct.Payable 6.23
8.58
7.85
6.37
13.92
growth rate 37.8% -8.5% -18.9% 118.7%
Cur.Assets 93.94
124.19
150.82
197.18
224.19
growth rate 32.2% 21.5% 30.7% 13.7%
Total Assets 110.67
220.54
242.98
274.38
299.75
growth rate 99.3% 10.2% 12.9% 9.3%
Cash 31.06
31.06
33.12
31.17
33.89
growth rate 0.0% 6.6% -5.9% 8.8%
Inventory 3.83
4.58
4.88
4.95
5.36
growth rate 19.5% 6.6% 1.5% 8.4%
Cur.Liabilities 24.37
29.57
27.75
30.87
40.21
growth rate 21.3% -6.2% 11.3% 30.2%
Liabilities 24.37
29.57
27.75
30.87
40.21
growth rate 21.3% -6.2% 11.3% 30.2%
LT Debt
growth rate
Equity 86.30
190.97
215.23
243.51
259.55
growth rate 121.3% 12.7% 13.1% 6.6%
Common Shares 0.11
0.12
0.12
0.12
0.12
growth rate 0.9% 0.0% 0.9% 0.0%
Cash Flow Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Capital Expenditures 0.08
0.03
0.08
0.06
0.05
growth rate -64.6% 165.5% -18.2% -28.6%
Cash Dividends
growth rate
Cash From OA 10.93
24.88
34.43
15.21
44.51
growth rate 127.8% 38.4% -55.8% 192.6%
Sale Purchase of Stock 2.77
1.92
1.92
growth rate -30.7% 0.0%
FCF 10.84
24.85
34.35
15.15
44.46
growth rate 129.2% 38.2% -55.9% 193.5%
Income Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Sales 42.76
53.28
57.66
62.31
64.45
growth rate 24.6% 8.2% 8.1% 3.4%
Op.Income 13.62
21.70
21.00
20.63
22.97
growth rate 59.3% -3.2% -1.7% 11.3%
IBT 13.71
21.89
21.29
21.20
23.73
growth rate 59.6% -2.7% -0.4% 12.0%
Net Income 13.76
98.33
17.46
18.20
17.75
growth rate 614.8% -82.2% 4.2% -2.5%
EPS
growth rate
Gross Profit 41.79
52.12
56.49
61.16
63.14
growth rate 24.7% 8.4% 8.3% 3.2%
R&D 11.69
13.63
17.05
20.54
18.86
growth rate 16.6% 25.1% 20.5% -8.2%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (79.01)

YOY Growth Grade:

E (29.43)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 9.88 9.88 15.13
EPS / Growth 0.0% 1.19 -1.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 17.0% 31.8%
Future PE 0.00 19.67 29.50
Future EPS 1.19 5.74 18.82
Value Price
MOS %
0.00
-100.0%
27.90
136.5%
137.21
1,062.8%
MOS Price 0.00 13.95 68.61
IRT 9.88 5.65 4.39

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.